Meniett Device Research Articles

Treatment of Meniere’s disease with the low-pressure pulse generator (Meniett device)

Until recently, surgery was the only treatment option for people with disabling Meniere’s disease that did not respond to adequate medical therapy. A new intermediate level treatment modality, the Meniett device, which applies low-pressure micropulses to the inner ear, has now been shown to be safe and effective. The device is portable and self-administered, requiring a 5-min three-times daily application for an indefinite period. Placement of a tympanostomy tube in the ear drum of the affected ear is necessary. Patient acceptance has been high. Long-term success in control of vertigo is over 80%. Although hearing loss is not improved, Meniett device usage does not adversely affect balance, as do most forms of surgical therapy. Use of the device does not preclude later surgical therapy.

Long-term effects of the Meniett device in Ménière’s disease: the Western Australian experience

Transtympanic pressure has been shown to influence endolymphatic hydrops. As endolymphatic hydrops plays a key role in Ménière's disease, a few studies, undertaken by the inventors, manufacturers and associates of the Meniett device, have demonstrated positive short-term effects of transtympanic pressure treatment via the Meniett device in medically intractable Ménière's disease. The aim of our study was to independently investigate the long-term efficacy and safety of transtympanic pressure treatment in the management of recalcitrant vertigo in Ménière's disease. Cross-sectional case study. Tertiary referral centre. Eighteen patients with Ménière's disease, suffering from medically intractable symptoms. All patients in the study had Ménière's disease according to the criteria of the Committee on Hearing and Equilibrium of the American Academy of Otolaryngology, Head & Neck Surgery. Outcome and severity of symptoms were assessed, using the six-point functional scale and the vertigo visual analogue scale (VAS), as recommended by the Committee on Hearing and Equilibrium of the American Academy of Otolaryngology, Head & Neck Surgery. Changes of pure tone average thresholds and vestibular calorics before and during treatment with the Meniett device were recorded. The mean follow-up time was 18 months. Twelve out of 18 patients showed significant improvement in the functional score and in the VAS. Five patients displayed an audiometric improvement, out of which three patients showed a pertaining significant hearing gain of more than 10 dB; the remainder had stable hearing levels. Of six patients without any improvement, four had previous invasive surgery for their Ménière's disease and two had previous vestibular ablation with gentamicin. No changes in vestibular function were noted. There were no complications during the treatment with the Meniett device. According to this independent study, the Meniett device seems to be a minimally invasive, non-destructive treatment tool, which can reduce vertigo and associated functional handicap in Ménière's disease. These effects are maintained up to 18 months after treatment so far. Previous surgical or chemical vestibular ablation procedures may adversely influence the effect of the Meniett device.

Trends in the diagnosis and the management of meniere’s disease: Results of a survey

To determine the practices of the American Neurotology Society (ANS) membership in the evaluation and treatment of the Meniere's patient. Prospective. Questionnaire. Respondents' response to questions pertaining to the diagnostic and therapeutic practices in the management of Meniere's disease. Three hundred members of ANS were mailed a 15-item questionnaire. Two hundred three responded, for a 67.7% response rate. For the diagnosis of Meniere's disease, 1 in 3 practitioners relied solely on history, physical exam, and audiometry, whereas 2 in 3 relied in part on adjunctive tests, such as electrocochleography (ECOG) and electronystagmography (ENG). Two in 3 practitioners pursued retrocochlear studies on initial evaluation, with the overwhelming majority using MRI. In treating Meniere's disease, conservative medical management was preferred. For medically recalcitrant Meniere's disease, endolymphatic sac surgery (ESS) was the most commonly employed initial intervention (50%), followed by transtympanic gentamicin (38%). Currently, <10% routinely recommend the Meniett device. Eighty-three percent include ESS as a therapeutic option for medically recalcitrant Meniere's disease. The vast majority continue to perform surgical labyrinthectomies and vestibular nerve sections for Meniere's disease. Meniere's disease continues to pose a difficult diagnostic and therapeutic problem, resulting in heterogeneous approaches to both evaluation and treatment. Despite the 1995 American Academy of Otolaryngology guidelines in the diagnosis of Meniere's disease, most clinicians rely in part on ENG or ECOG in diagnosing Meniere's disease. Furthermore, despite the passing of 20 years since the publications claiming a purely placebo effect, ESS is the most commonly employed initial surgical treatment for Meniere's disease.

Intermittent pressure therapy of intractable Ménière's disease using the Meniett device: a preliminary report.

Treatment with the Meniett device, which applies intermittent micropressure pulses to the inner ear through a tympanostomy tube, is effective in controlling vertigo in people with intractable Ménière's disease. Short-term, preliminary descriptive report. Ten patients with intractable vertigo despite adequate medical therapy elected to use the Meniett device. After placement of a standard tympanostomy tube, the patient self-administers the Meniett device three times daily. The follow-up ranged from 3 to 11 months with an average of 8 months. All 10 patients responded to the therapy with vertigo control in 9 of 10 and a 50% reduction in the 10th case. There was a mean hearing gain of 6 dB, which was statistically significant. There were no major complications. Two subjects required tube reinsertion during the 8 months of follow-up. Use of the Meniett device is an effective and safe option for people with intractable vertigo from Ménière's disease.